EQRx International, Inc.
🇺🇸United States
Clinical Trials
8
Active:1
Completed:3
Trial Phases
2 Phases
Phase 1:5
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (71.4%)Phase 3
2 (28.6%)Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
Phase 3
Withdrawn
- Conditions
- Endometrial Carcinoma
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- EQRx International, Inc.
- Registration Number
- NCT05712941
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
Phase 3
Terminated
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- EQRx International, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05493501
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸Memorial Cancer Institute, Pembroke Pines, Florida, United States
🇺🇸QCCA - Mission Blood & Cancer, Des Moines, Iowa, United States
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143
Phase 1
Completed
- Conditions
- Severe Hepatic Impairment
- Interventions
- Drug: aumolertinib
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- EQRx International, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05199610
- Locations
- 🇺🇸
American Institute Research, Los Angeles, California, United States
🇺🇸Global Clinical Professionals, Saint Petersburg, Florida, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
- Conditions
- Extranodal NK/T-cell Lymphoma
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- EQRx International, Inc.
- Registration Number
- NCT05131438
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
News
No news found